161 related articles for article (PubMed ID: 20121115)
1. Insight into binding of phosphodiesterase-9A selective inhibitors by crystal structures and mutagenesis.
Wang H; Luo X; Ye M; Hou J; Robinson H; Ke H
J Med Chem; 2010 Feb; 53(4):1726-31. PubMed ID: 20121115
[TBL] [Abstract][Full Text] [Related]
2. Structure-based discovery of highly selective phosphodiesterase-9A inhibitors and implications for inhibitor design.
Meng F; Hou J; Shao YX; Wu PY; Huang M; Zhu X; Cai Y; Li Z; Xu J; Liu P; Luo HB; Wan Y; Ke H
J Med Chem; 2012 Oct; 55(19):8549-58. PubMed ID: 22985069
[TBL] [Abstract][Full Text] [Related]
3. Structural Asymmetry of Phosphodiesterase-9A and a Unique Pocket for Selective Binding of a Potent Enantiomeric Inhibitor.
Huang M; Shao Y; Hou J; Cui W; Liang B; Huang Y; Li Z; Wu Y; Zhu X; Liu P; Wan Y; Ke H; Luo HB
Mol Pharmacol; 2015 Nov; 88(5):836-45. PubMed ID: 26316540
[TBL] [Abstract][Full Text] [Related]
4. Structural asymmetry of phosphodiesterase-9, potential protonation of a glutamic acid, and role of the invariant glutamine.
Hou J; Xu J; Liu M; Zhao R; Luo HB; Ke H
PLoS One; 2011 Mar; 6(3):e18092. PubMed ID: 21483814
[TBL] [Abstract][Full Text] [Related]
5. Identification of overlapping but distinct cAMP and cGMP interaction sites with cyclic nucleotide phosphodiesterase 3A by site-directed mutagenesis and molecular modeling based on crystalline PDE4B.
Zhang W; Ke H; Tretiakova AP; Jameson B; Colman RW
Protein Sci; 2001 Aug; 10(8):1481-9. PubMed ID: 11468344
[TBL] [Abstract][Full Text] [Related]
6. Enantiomer discrimination illustrated by the high resolution crystal structures of type 4 phosphodiesterase.
Huai Q; Sun Y; Wang H; Macdonald D; Aspiotis R; Robinson H; Huang Z; Ke H
J Med Chem; 2006 Mar; 49(6):1867-73. PubMed ID: 16539372
[TBL] [Abstract][Full Text] [Related]
7. Structural determinants for inhibitor specificity and selectivity in PDE2A using the wheat germ in vitro translation system.
Iffland A; Kohls D; Low S; Luan J; Zhang Y; Kothe M; Cao Q; Kamath AV; Ding YH; Ellenberger T
Biochemistry; 2005 Jun; 44(23):8312-25. PubMed ID: 15938621
[TBL] [Abstract][Full Text] [Related]
8. Kinetic and structural studies of phosphodiesterase-8A and implication on the inhibitor selectivity.
Wang H; Yan Z; Yang S; Cai J; Robinson H; Ke H
Biochemistry; 2008 Dec; 47(48):12760-8. PubMed ID: 18983167
[TBL] [Abstract][Full Text] [Related]
9. Molecular dynamics-based discovery of novel phosphodiesterase-9A inhibitors with non-pyrazolopyrimidinone scaffolds.
Li Z; Lu X; Feng LJ; Gu Y; Li X; Wu Y; Luo HB
Mol Biosyst; 2015 Jan; 11(1):115-25. PubMed ID: 25328054
[TBL] [Abstract][Full Text] [Related]
10. Multiple elements jointly determine inhibitor selectivity of cyclic nucleotide phosphodiesterases 4 and 7.
Wang H; Liu Y; Chen Y; Robinson H; Ke H
J Biol Chem; 2005 Sep; 280(35):30949-55. PubMed ID: 15994308
[TBL] [Abstract][Full Text] [Related]
11. Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors.
Claffey MM; Helal CJ; Verhoest PR; Kang Z; Fors KS; Jung S; Zhong J; Bundesmann MW; Hou X; Lui S; Kleiman RJ; Vanase-Frawley M; Schmidt AW; Menniti F; Schmidt CJ; Hoffman WE; Hajos M; McDowell L; O'Connor RE; Macdougall-Murphy M; Fonseca KR; Becker SL; Nelson FR; Liras S
J Med Chem; 2012 Nov; 55(21):9055-68. PubMed ID: 23025719
[TBL] [Abstract][Full Text] [Related]
12. Identification of inhibitor binding sites of the cAMP-specific phosphodiesterase 4.
Richter W; Unciuleac L; Hermsdorf T; Kronbach T; Dettmer D
Cell Signal; 2001 Apr; 13(4):287-97. PubMed ID: 11306246
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a phosphodiesterase 9A inhibitor as a potential hypoglycemic agent.
Shao YX; Huang M; Cui W; Feng LJ; Wu Y; Cai Y; Li Z; Zhu X; Liu P; Wan Y; Ke H; Luo HB
J Med Chem; 2014 Dec; 57(24):10304-13. PubMed ID: 25432025
[TBL] [Abstract][Full Text] [Related]
14. Crystal structure of phosphodiesterase 4D and inhibitor complex(1).
Lee ME; Markowitz J; Lee JO; Lee H
FEBS Lett; 2002 Oct; 530(1-3):53-8. PubMed ID: 12387865
[TBL] [Abstract][Full Text] [Related]
15. Phosphodiesterase 9: insights from protein structure and role in therapeutics.
Singh N; Patra S
Life Sci; 2014 Jun; 106(1-2):1-11. PubMed ID: 24746902
[TBL] [Abstract][Full Text] [Related]
16. Computational Study on Selective PDE9 Inhibitors on PDE9-Mg/Mg, PDE9-Zn/Mg, and PDE9-Zn/Zn Systems.
Sivakumar D; Mudedla S; Jang S; Kim H; Park H; Choi Y; Oh J; Wu S
Biomolecules; 2021 May; 11(5):. PubMed ID: 34068780
[TBL] [Abstract][Full Text] [Related]
17. Crystal structure of human phosphodiesterase 3B: atomic basis for substrate and inhibitor specificity.
Scapin G; Patel SB; Chung C; Varnerin JP; Edmondson SD; Mastracchio A; Parmee ER; Singh SB; Becker JW; Van der Ploeg LH; Tota MR
Biochemistry; 2004 May; 43(20):6091-100. PubMed ID: 15147193
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line.
Wunder F; Tersteegen A; Rebmann A; Erb C; Fahrig T; Hendrix M
Mol Pharmacol; 2005 Dec; 68(6):1775-81. PubMed ID: 16150925
[TBL] [Abstract][Full Text] [Related]
19. Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram.
Xu RX; Rocque WJ; Lambert MH; Vanderwall DE; Luther MA; Nolte RT
J Mol Biol; 2004 Mar; 337(2):355-65. PubMed ID: 15003452
[TBL] [Abstract][Full Text] [Related]
20. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents.
Hutson PH; Finger EN; Magliaro BC; Smith SM; Converso A; Sanderson PE; Mullins D; Hyde LA; Eschle BK; Turnbull Z; Sloan H; Guzzi M; Zhang X; Wang A; Rindgen D; Mazzola R; Vivian JA; Eddins D; Uslaner JM; Bednar R; Gambone C; Le-Mair W; Marino MJ; Sachs N; Xu G; Parmentier-Batteur S
Neuropharmacology; 2011 Sep; 61(4):665-76. PubMed ID: 21619887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]